CARE-MS I & II articles: free access

Genzyme has kindly made digital access to the CARE-MS I & II publications free:


Epub: Cohen JA, Coles AJ, Arnold DL, Confavreux C,Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV,Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA,Compston DAS; for the CARE-MS I investigators. Alemtuzumab versus interferonbeta 1a as first-line treatment for patients with relapsing-remitting multiplesclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 01.doi: 10.1016/S0140-6736(12)61769-3. Online supplement          


Epub: Coles AJ, Twyman CL, Arnold DL, Cohen JA,Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T,Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, CompstonDAS; for the CARE-MS II investigators. Alemtuzumab for patients with relapsingmultiple sclerosis after disease-modifying therapy: a randomised controlledphase 3 trial. Lancet. 2012 Nov 01. doi: 10.1016/S0140-6736(12)61768-1. Online supplement

CoI: multiple